FDA Clears Teva’s Breath-Actuated Inhaler
Teva Pharmaceuticals announced FDA approval for its QVAR RediHaler, a breath-actuated inhaler for asthma in children 4 years or older.
The device delivers a metered dose through breath-activation, leaving no need for hand-breath coordination. Teva’s QVAR metered-distribution inhaler hit the market in 2014. As part of the launch of the RediHaler, the company will discontinue the older device.
The RediHaler is expected to be commercially available during the first quarter of next year.